Acne Vulgaris - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 147 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Acne Vulgaris - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Acne Vulgaris - Pipeline Review, H2 2014', provides an overview of the Acne Vulgaris's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acne Vulgaris, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acne Vulgaris and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acne Vulgaris
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Acne Vulgaris and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Acne Vulgaris products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Acne Vulgaris pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Acne Vulgaris
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Acne Vulgaris pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Acne Vulgaris Overview 11
Therapeutics Development 12
Pipeline Products for Acne Vulgaris - Overview 12
Pipeline Products for Acne Vulgaris - Comparative Analysis 13
Acne Vulgaris - Therapeutics under Development by Companies 14
Acne Vulgaris - Therapeutics under Investigation by Universities/Institutes 17
Acne Vulgaris - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Acne Vulgaris - Products under Development by Companies 22
Acne Vulgaris - Products under Investigation by Universities/Institutes 23
Acne Vulgaris - Companies Involved in Therapeutics Development 24
Boehringer Ingelheim GmbH 24
Photocure ASA 25
Allergan, Inc. 26
Valeant Pharmaceuticals International, Inc. 27
GlaxoSmithKline plc 28
Galderma S.A. 29
Toyama Chemical Co., Ltd. 30
AntiCancer, Inc. 31
Cosmo Pharmaceuticals S.p.A 32
XOMA Corporation 33
Provectus Biopharmaceuticals, Inc. 34
Deltanoid Pharmaceuticals Inc. 35
Phosphagenics Limited 36
Foamix Ltd. 37
AndroScience Corporation 38
ELORAC, Inc. 39
Cutanea Life Sciences 40
Braintree Laboratories, Inc. 41
Maruho Co., Ltd. 42
RestorGenex Corporation 43
Ensoltek Co., Ltd. 44
Ausio Pharmaceuticals, LLC 45
XBiotech USA, Inc. 46
Advancell 47
Celtaxsys, Inc. 48
Delenex Therapeutics AG 49
Dermira Inc. 50
Kasiak Research Pvt. Ltd. 51
Biomar Microbial Technologies 52
Thesan Pharmaceuticals, Inc. 53
OrigImm e.U. 54
Acne Vulgaris - Therapeutics Assessment 55
Assessment by Monotherapy Products 55
Assessment by Combination Products 56
Assessment by Target 57
Assessment by Mechanism of Action 60
Assessment by Route of Administration 63
Assessment by Molecule Type 65
Drug Profiles 67
(adapalene + benzoyl peroxide) - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
ozenoxacin - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
trifarotene - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
benzoyl peroxide - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Aczone X - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
omiganan pentahydrochloride - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
tretinoin - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
ASCJ-9 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
AUS-131 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
methyl aminolevulinate hydrochloride - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
gevokizumab - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
CB-0301 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
minocycline - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
DRM-01 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
BLI-1100 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
CD2475/101 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
JNJ-10229570-AAA - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
RA-18C3 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
NVN-1000 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
onabotulinumtoxin A - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Refaglo - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
finasteride - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
CB-0601 - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
CB-0604 - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
GSK-1940029 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
E-10215 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
FX-125L - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
PH-10 - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
RES-440 - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
becocalcidiol - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
CTX-4430 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
DLX-2323 - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
ANs-29 - Drug Profile 112
Product Description 112
Mechanism of Action 112
R&D Progress 112
AD-037 - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
Vaccine for Acne and Related Disorders - Drug Profile 114
Product Description 114
Mechanism of Action 114
R&D Progress 114
salicylic acid - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
Small Molecule for Acne and Inflammatory Skin Diseases - Drug Profile 116
Product Description 116
Mechanism of Action 116
R&D Progress 116
DLX-2681 - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
Lipo-4MA - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Peptide to Disrupt Bacterial Cell Membrane and Cell Wall for Acne And Skin Cancer - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
Hesed-4000 - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
Small Molecule for Acne - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
Drugs for Acne - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
Vaccine for Acne Vulgaris - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
Acne Vulgaris - Recent Pipeline Updates 125
Acne Vulgaris - Dormant Projects 137
Acne Vulgaris - Discontinued Products 138
Acne Vulgaris - Product Development Milestones 139
Featured News & Press Releases 139
May 08, 2014: Novan Therapeutics' Positive Phase 2 Results Provide Foundation for SB204 as a Non-Antibiotic, First-in-Class Product to Treat Acne Vulgaris 139
Apr 23, 2014: Novan Therapeutics' Abstract Accepted for Poster Session at 2014 Society for Investigative Dermatology Annual Meeting 139
Apr 23, 2014: Phosphagenics Completes Enrolment in Phase 2 Acne Treatment Trial 140
Mar 19, 2014: Novan Announces Positive Phase 2 Results for Novel Acne Treatment 140
Jun 25, 2013: Xoma's Development Partner Servier Launches Proof-of-concept Clinical Program for Gevokizumab 141
Feb 28, 2013: Meda's Acnex Receives Registration Approval In Europe 142
Feb 28, 2013: Novan Therapeutics On Path To Develop First Topical Acne Treatment 142
Feb 19, 2013: Galderma's Epiduo Gel Obtains FDA Approval To Treat Acne In Children As Young As Nine Years Old 143
Jan 07, 2013: Xoma Announces Positive Interim Results From Gevokizumab Phase II Study For Moderate To Severe Acne Vulgaris 144
Dec 12, 2012: XBiotech Announces Positive Phase II Clinical Trial Results For MABp1 In Acne Vulgaris 145
Appendix 146
Methodology 146
Coverage 146
Secondary Research 146
Primary Research 146
Expert Panel Validation 146
Contact Us 147
Disclaimer 147

List of Tables
Number of Products under Development for Acne Vulgaris, H2 2014 12
Number of Products under Development for Acne Vulgaris - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 15
Number of Products under Investigation by Universities/Institutes, H2 2014 17
Comparative Analysis by Late Stage Development, H2 2014 18
Comparative Analysis by Clinical Stage Development, H2 2014 19
Comparative Analysis by Early Stage Development, H2 2014 20
Comparative Analysis by Unknown Stage Development, H2 2014 21
Products under Development by Companies, H2 2014 22
Products under Investigation by Universities/Institutes, H2 2014 23
Acne Vulgaris - Pipeline by Boehringer Ingelheim GmbH, H2 2014 24
Acne Vulgaris - Pipeline by Photocure ASA, H2 2014 25
Acne Vulgaris - Pipeline by Allergan, Inc., H2 2014 26
Acne Vulgaris - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2014 27
Acne Vulgaris - Pipeline by GlaxoSmithKline plc, H2 2014 28
Acne Vulgaris - Pipeline by Galderma S.A., H2 2014 29
Acne Vulgaris - Pipeline by Toyama Chemical Co., Ltd., H2 2014 30
Acne Vulgaris - Pipeline by AntiCancer, Inc., H2 2014 31
Acne Vulgaris - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2014 32
Acne Vulgaris - Pipeline by XOMA Corporation, H2 2014 33
Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals, Inc., H2 2014 34
Acne Vulgaris - Pipeline by Deltanoid Pharmaceuticals Inc., H2 2014 35
Acne Vulgaris - Pipeline by Phosphagenics Limited, H2 2014 36
Acne Vulgaris - Pipeline by Foamix Ltd., H2 2014 37
Acne Vulgaris - Pipeline by AndroScience Corporation, H2 2014 38
Acne Vulgaris - Pipeline by ELORAC, Inc., H2 2014 39
Acne Vulgaris - Pipeline by Cutanea Life Sciences, H2 2014 40
Acne Vulgaris - Pipeline by Braintree Laboratories, Inc., H2 2014 41
Acne Vulgaris - Pipeline by Maruho Co., Ltd., H2 2014 42
Acne Vulgaris - Pipeline by RestorGenex Corporation, H2 2014 43
Acne Vulgaris - Pipeline by Ensoltek Co., Ltd., H2 2014 44
Acne Vulgaris - Pipeline by Ausio Pharmaceuticals, LLC, H2 2014 45
Acne Vulgaris - Pipeline by XBiotech USA, Inc., H2 2014 46
Acne Vulgaris - Pipeline by Advancell, H2 2014 47
Acne Vulgaris - Pipeline by Celtaxsys, Inc., H2 2014 48
Acne Vulgaris - Pipeline by Delenex Therapeutics AG, H2 2014 49
Acne Vulgaris - Pipeline by Dermira Inc., H2 2014 50
Acne Vulgaris - Pipeline by Kasiak Research Pvt. Ltd., H2 2014 51
Acne Vulgaris - Pipeline by Biomar Microbial Technologies, H2 2014 52
Acne Vulgaris - Pipeline by Thesan Pharmaceuticals, Inc., H2 2014 53
Acne Vulgaris - Pipeline by OrigImm e.U., H2 2014 54
Assessment by Monotherapy Products, H2 2014 55
Assessment by Combination Products, H2 2014 56
Number of Products by Stage and Target, H2 2014 59
Number of Products by Stage and Mechanism of Action, H2 2014 62
Number of Products by Stage and Route of Administration, H2 2014 64
Number of Products by Stage and Molecule Type, H2 2014 66
Acne Vulgaris Therapeutics - Recent Pipeline Updates, H2 2014 125
Acne Vulgaris - Dormant Projects, H2 2014 137
Acne Vulgaris - Discontinued Products, H2 2014 138